PE Anti-NMDAR2B antibody [S59]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

NMDAR2B also known as NR2B or GluN2B functions as a subunit of the NMDA receptor complex. It plays a role in synaptic transmission and plasticity in the central nervous system. The target weighs approximately 166 kDa. It is highly expressed in the cerebral cortex hippocampus and striatum. NMDAR2B interacts with other subunits in the NMDA receptor which assemble to form a functional ion channel that allows for calcium ion influx when activated by glutamate and glycine.

Biological function summary

The NMDAR2B subunit contributes to the regulation of synaptic strength and is essential for processes involved in learning and memory. As part of the NMDA receptor complex it mediates excitatory neurotransmission and is involved in synaptic plasticity processes such as long-term potentiation (LTP). These functions are significant for cognitive function and neural development. The receptor's role in signal transduction is aided by the unique properties conferred by the NMDAR2B subunit such as its high affinity for glycine and slower deactivation kinetics.

Pathways

NMDAR2B is involved in the glutamatergic signaling pathway which is important for neural communication. It also participates in the calcium signaling pathway affecting cellular responses to external stimuli. The protein interacts with CaMKII and PSD-95 which are proteins that influence synaptic strength and architecture through these pathways. Its involvement links it to a variety of signaling events important for brain function.

Associated diseases and disorders

Alterations in NMDAR2B have been associated with neurodegenerative conditions such as Alzheimer's disease and neurodevelopmental disorders like schizophrenia. The protein's malfunction can lead to abnormal synaptic connectivity and excitotoxicity. It is linked to other proteins associated with these diseases such as beta-amyloid in Alzheimer's and dopamine receptor dysregulation in schizophrenia indicating its role in disease progression and symptom manifestation.